852 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
CELG Celgene Corporation $87.23 $61.35B N/A
Article Searches
3 Big Biotechs Hold Growth Potential in Second Half of 2019 http://www.zacks.com/stock/news/432820/3-big-biotechs-hold-growth-potential-in-second-half-of-2019?cid=CS-ZC-FT-432820 Jun 21, 2019 - We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.
Alexion's (ALXN) Ultomiris Gets Approval in Japan for PNH http://www.zacks.com/stock/news/431825/alexions-alxn-ultomiris-gets-approval-in-japan-for-pnh?cid=CS-ZC-FT-431825 Jun 19, 2019 - Alexion (ALXN) receives approval in Japan for its long-acting C5 complement inhibitor, Ultomiris, for the PHN indication.
Big Drugmakers That May Tread the M&A Path After Pfizer http://www.zacks.com/stock/news/431504/big-drugmakers-that-may-tread-the-ma-path-after-pfizer?cid=CS-ZC-FT-431504 Jun 19, 2019 - There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.
Celgene (CELG) Hits 52-Week High, Can the Run Continue? http://www.zacks.com/stock/news/431052/celgene-celg-hits-52-week-high-can-the-run-continue?cid=CS-ZC-FT-431052 Jun 18, 2019 - Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz http://www.zacks.com/stock/news/430687/novartis-nvs-announces-promising-data-on-tasigna-hyrimoz?cid=CS-ZC-FT-430687 Jun 17, 2019 - Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.
Regeneron (REGN) Presents Positive Data on Lymphoma Candidate http://www.zacks.com/stock/news/430443/regeneron-regn-presents-positive-data-on-lymphoma-candidate?cid=CS-ZC-FT-430443 Jun 17, 2019 - Regeneron (REGN) reports positive early-stage data on REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma.
Is It Too Late to Buy Celgene Stock? https://www.fool.com/investing/2019/06/16/is-it-too-late-to-buy-celgene-stock.aspx?source=iedfolrf0000001 Jun 16, 2019 - The clock is ticking for Celgene's acquisition by Bristol-Myers Squibb. But is Celgene still a stock worth buying?
Mallinckrodt Presents Encouraging Data on Acthar Gel for RA http://www.zacks.com/stock/news/429638/mallinckrodt-presents-encouraging-data-on-acthar-gel-for-ra?cid=CS-ZC-FT-429638 Jun 14, 2019 - Mallinckrodt (MNK) reports encouraging results from a phase IV study on Acthar for RA at the EULAR.
Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash http://www.zacks.com/stock/news/428419/biotech-stock-roundup-celgene-submits-ms-drug-to-fda-insy-cbay-crash?cid=CS-ZC-FT-428419 Jun 12, 2019 - Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Boost Your Portfolio's Health With These 3 Big Drug Stocks http://www.zacks.com/stock/news/428332/boost-your-portfolios-health-with-these-3-big-drug-stocks?cid=CS-ZC-FT-428332 Jun 12, 2019 - The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.

Pages: 123456...86

Page 1>